Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings

Marika Alborghetti; Edoardo Bianchini; Lanfranco De Carolis; Silvia Galli; Francesco E.Pontieri; Domiziana Rinaldi

doi:10.4103/1673-5374.375299

🤖This page has been translated by AI and may contain inaccuracies. Please refer to the original content for clarification.

Home>Articles>Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings

DOI: 10.4103/1673-5374.375299

Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings

Marika Alborghetti

Edoardo Bianchini

Lanfranco De Carolis

Silvia Galli

Francesco E.Pontieri

Domiziana Rinaldi

Keywords：glial cell line-derived neurotrophic factor(GDNF)glutamateneurological disordersneuroprotectionParkinson's diseasepreclinical studiesrasagilinesafinamideselegilinetype-B monoamine oxidase(MAOB)inhibitors

Publication Date：2024-01-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 16-21 )

Neural Regeneration Research

ISSN：1673-5374

Year, Vol.(Issue)：2024,19(1)